跳至主要内容
临床试验/NL-OMON44854
NL-OMON44854已完成不适用

Watchful waiting in patients with good and intermediate risk metastatic renal cell carcinoma; an imaging guided observational approach - IMPACT - Renal Watch

Radboud Universitair Medisch Centrum0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Able to provide written informed consent
  • - Age >= 18 years
  • - Histological or cytological documented RCC with a clear cell component
  • - Good or intermediate prognosis, defined as none (good risk) or 1-2 (intermediate risk) of the below mentioned risk factors (6):
  • o Karnofsky performance <80
  • o Time from diagnosis detection of metastases < 1 year
  • o Haemoglobin < lower limit of normal (LLN)
  • o Corrected calcium > upper limit of normal (ULN)
  • o Neutrophils > ULN
  • o Platelets > ULN
  • - A watchful waiting period for 2 months is considered an option according to treating medical oncologist
  • - No prior systemic treatment for RCC (also non-adjuvant)

排除标准

  • - Untreated central nervous system metastases, or symptomatic intracerebral metastases.
  • - Pregnant or breast feeding women.
  • - Any serious and/or unstable pre-existing medical, psychiatric, or other condition that would make the subject inappropriate for study participation including any serious condition that could interfere with subject*s safety, provision of informed consent, or compliance with study procedure.

研究者

相似试验